We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
First-in-class anemia drug takes aim at Amgen's dominion.
- Authors
Bouchie, Aaron
- Abstract
The article offers information on collaborative efforts of San Francisco–based biotech FibroGen and London-based AstraZeneca to jointly develop the oral drug FG-4592, first-in-class anemia agent. It mentions that FG-4592 is current under phase three of clinical trials where it is being used to treat patients with chronic kidney disease (CKD). It informs that AstraZeneca and FibroGen are betting to dominate the recombinant EPO Epogen (epoetin alfa) being offered by Amgen in the U.S.
- Subjects
FIBROGEN Inc.; ASTRAZENECA PLC; CLINICAL trials; ANEMIA treatment; KIDNEY disease treatments; EPOETIN alfa (Drug); AMGEN Inc.
- Publication
Nature Biotechnology, 2013, Vol 31, Issue 11, p948
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt1113-948b